A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA).

Trial Profile

A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA).

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Ferumoxytol (Primary) ; Ferric carboxymaltose
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions; Registrational
  • Acronyms FIRM
  • Sponsors AMAG Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 06 Nov 2017 Results presented in an AMAG Pharmaceuticals Media Release.
    • 06 Nov 2017 According to an AMAG Pharmaceuticals media release, data were presented at the 2017 American Society of Nephrology (ASN) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top